Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Basal Cell | 30 | 2024 | 290 | 10.180 |
Why?
|
| Skin Neoplasms | 51 | 2024 | 4888 | 6.320 |
Why?
|
| Biphenyl Compounds | 10 | 2023 | 192 | 3.090 |
Why?
|
| Carcinoma, Squamous Cell | 17 | 2024 | 5601 | 2.990 |
Why?
|
| Pyridines | 18 | 2023 | 1311 | 2.610 |
Why?
|
| Hedgehog Proteins | 16 | 2024 | 441 | 2.230 |
Why?
|
| Mohs Surgery | 7 | 2023 | 102 | 2.140 |
Why?
|
| Anilides | 11 | 2024 | 296 | 1.740 |
Why?
|
| Antibodies, Monoclonal, Humanized | 12 | 2024 | 3391 | 1.580 |
Why?
|
| Antineoplastic Agents | 18 | 2024 | 14653 | 1.280 |
Why?
|
| Skin Diseases | 3 | 2022 | 365 | 1.270 |
Why?
|
| Antineoplastic Agents, Immunological | 5 | 2024 | 1335 | 1.250 |
Why?
|
| Programmed Cell Death 1 Receptor | 6 | 2021 | 1089 | 1.160 |
Why?
|
| Dermatology | 2 | 2022 | 72 | 0.970 |
Why?
|
| Injections, Intralesional | 1 | 2024 | 166 | 0.920 |
Why?
|
| Leg Dermatoses | 2 | 2021 | 7 | 0.880 |
Why?
|
| Cicatrix | 2 | 2023 | 187 | 0.870 |
Why?
|
| Tattooing | 1 | 2021 | 16 | 0.780 |
Why?
|
| Photography | 2 | 2022 | 125 | 0.770 |
Why?
|
| Intertrigo | 1 | 2020 | 1 | 0.730 |
Why?
|
| Medicine | 1 | 2022 | 140 | 0.730 |
Why?
|
| Nose Neoplasms | 1 | 2023 | 236 | 0.730 |
Why?
|
| Dermatologic Agents | 2 | 2019 | 44 | 0.700 |
Why?
|
| Dermatologic Surgical Procedures | 2 | 2017 | 106 | 0.700 |
Why?
|
| Myxedema | 1 | 2019 | 7 | 0.690 |
Why?
|
| Basal Cell Nevus Syndrome | 2 | 2016 | 20 | 0.690 |
Why?
|
| Pentoxifylline | 1 | 2019 | 37 | 0.680 |
Why?
|
| Scalp | 2 | 2018 | 155 | 0.670 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2020 | 562 | 0.660 |
Why?
|
| Immunotherapy | 5 | 2024 | 3539 | 0.650 |
Why?
|
| Frontal Sinus | 1 | 2018 | 15 | 0.640 |
Why?
|
| Surgical Flaps | 2 | 2022 | 882 | 0.640 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2018 | 33 | 0.640 |
Why?
|
| Mucocele | 1 | 2018 | 24 | 0.630 |
Why?
|
| Traction | 1 | 2017 | 12 | 0.610 |
Why?
|
| Hemostasis, Surgical | 1 | 2017 | 55 | 0.600 |
Why?
|
| Computers, Handheld | 1 | 2018 | 61 | 0.590 |
Why?
|
| Clinical Protocols | 1 | 2020 | 485 | 0.580 |
Why?
|
| Humans | 72 | 2024 | 271636 | 0.570 |
Why?
|
| Antibodies, Monoclonal | 3 | 2024 | 4495 | 0.550 |
Why?
|
| Skin | 3 | 2018 | 1284 | 0.540 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 294 | 0.530 |
Why?
|
| Glucocorticoids | 1 | 2019 | 621 | 0.510 |
Why?
|
| Molecular Targeted Therapy | 7 | 2021 | 2398 | 0.500 |
Why?
|
| Venous Insufficiency | 3 | 2021 | 20 | 0.490 |
Why?
|
| Dermatitis | 3 | 2021 | 63 | 0.470 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 1444 | 0.420 |
Why?
|
| Treatment Outcome | 15 | 2021 | 33846 | 0.410 |
Why?
|
| Aged | 29 | 2023 | 73421 | 0.390 |
Why?
|
| Neoplasm Metastasis | 8 | 2021 | 5328 | 0.380 |
Why?
|
| Neoplasm Staging | 10 | 2021 | 13989 | 0.370 |
Why?
|
| Head and Neck Neoplasms | 6 | 2023 | 4136 | 0.360 |
Why?
|
| Smoothened Receptor | 4 | 2018 | 53 | 0.360 |
Why?
|
| Male | 33 | 2023 | 128836 | 0.340 |
Why?
|
| Melanoma | 3 | 2024 | 5591 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 10354 | 0.320 |
Why?
|
| Biopsy | 4 | 2021 | 3544 | 0.310 |
Why?
|
| Aged, 80 and over | 16 | 2021 | 31032 | 0.300 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2018 | 70 | 0.290 |
Why?
|
| Video Recording | 1 | 2008 | 274 | 0.270 |
Why?
|
| Female | 32 | 2023 | 148992 | 0.250 |
Why?
|
| Follow-Up Studies | 9 | 2023 | 15254 | 0.250 |
Why?
|
| Middle Aged | 24 | 2023 | 90349 | 0.250 |
Why?
|
| Corneal Diseases | 2 | 1996 | 105 | 0.250 |
Why?
|
| Informed Consent | 1 | 2008 | 413 | 0.240 |
Why?
|
| Image Enhancement | 1 | 2008 | 555 | 0.230 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 440 | 0.230 |
Why?
|
| Adult | 21 | 2024 | 81791 | 0.220 |
Why?
|
| Dermatologists | 1 | 2022 | 4 | 0.220 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 746 | 0.210 |
Why?
|
| Prognosis | 7 | 2024 | 22525 | 0.210 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 916 | 0.210 |
Why?
|
| Cheek | 1 | 2022 | 57 | 0.200 |
Why?
|
| Nose | 1 | 2023 | 140 | 0.200 |
Why?
|
| Oncolytic Virotherapy | 1 | 2024 | 235 | 0.200 |
Why?
|
| Dysgeusia | 1 | 2021 | 6 | 0.190 |
Why?
|
| Spasm | 1 | 2021 | 59 | 0.190 |
Why?
|
| Arm | 1 | 2021 | 138 | 0.190 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2023 | 330 | 0.190 |
Why?
|
| Allografts | 1 | 2023 | 684 | 0.180 |
Why?
|
| Vasculitis | 1 | 2021 | 77 | 0.180 |
Why?
|
| Herpesvirus 3, Human | 1 | 2000 | 44 | 0.180 |
Why?
|
| Disease-Free Survival | 5 | 2023 | 10259 | 0.180 |
Why?
|
| Alopecia | 1 | 2021 | 124 | 0.180 |
Why?
|
| Groin | 1 | 2020 | 78 | 0.180 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 9042 | 0.180 |
Why?
|
| Stockings, Compression | 1 | 2019 | 5 | 0.170 |
Why?
|
| Germany | 1 | 2020 | 124 | 0.170 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2000 | 269 | 0.170 |
Why?
|
| Graves Disease | 1 | 2019 | 48 | 0.170 |
Why?
|
| Australia | 1 | 2020 | 261 | 0.170 |
Why?
|
| Fat Necrosis | 1 | 2019 | 59 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 565 | 0.160 |
Why?
|
| Double-Blind Method | 4 | 2020 | 2619 | 0.160 |
Why?
|
| Acrospiroma | 1 | 2018 | 12 | 0.160 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2019 | 162 | 0.160 |
Why?
|
| Forehead | 1 | 2018 | 26 | 0.160 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 3852 | 0.160 |
Why?
|
| Placenta | 1 | 2023 | 565 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2022 | 668 | 0.160 |
Why?
|
| Scleroderma, Localized | 1 | 2018 | 13 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2021 | 5102 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 533 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 686 | 0.150 |
Why?
|
| Vascular Neoplasms | 1 | 2018 | 113 | 0.150 |
Why?
|
| Adenoma, Sweat Gland | 1 | 2017 | 13 | 0.150 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 10743 | 0.150 |
Why?
|
| Time Factors | 4 | 2020 | 13116 | 0.150 |
Why?
|
| Cetuximab | 1 | 2019 | 474 | 0.140 |
Why?
|
| Astrocytoma | 1 | 2019 | 335 | 0.140 |
Why?
|
| Keratoplasty, Penetrating | 1 | 1996 | 55 | 0.140 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2018 | 235 | 0.140 |
Why?
|
| Eye Infections, Viral | 1 | 1996 | 29 | 0.140 |
Why?
|
| Skull | 1 | 2018 | 252 | 0.140 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1996 | 89 | 0.140 |
Why?
|
| Keratosis, Actinic | 1 | 2016 | 39 | 0.140 |
Why?
|
| Documentation | 1 | 2018 | 215 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2023 | 6266 | 0.130 |
Why?
|
| Treatment Failure | 1 | 2019 | 1432 | 0.130 |
Why?
|
| Nevus | 1 | 2016 | 117 | 0.130 |
Why?
|
| Phthalazines | 1 | 2018 | 263 | 0.130 |
Why?
|
| Retrospective Studies | 9 | 2023 | 39731 | 0.130 |
Why?
|
| Photorefractive Keratectomy | 1 | 1996 | 81 | 0.130 |
Why?
|
| Disease Management | 1 | 2021 | 1111 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 721 | 0.120 |
Why?
|
| Insurance, Health | 1 | 2017 | 262 | 0.120 |
Why?
|
| Suture Techniques | 1 | 2016 | 292 | 0.120 |
Why?
|
| Hepatitis B virus | 1 | 1996 | 224 | 0.120 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 681 | 0.120 |
Why?
|
| Cornea | 2 | 1996 | 678 | 0.120 |
Why?
|
| Signal Transduction | 5 | 2021 | 12219 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 1 | 2000 | 3512 | 0.110 |
Why?
|
| Ipilimumab | 1 | 2019 | 759 | 0.110 |
Why?
|
| Hepatitis B | 1 | 1996 | 273 | 0.110 |
Why?
|
| Cost of Illness | 1 | 2017 | 505 | 0.110 |
Why?
|
| Pilot Projects | 2 | 2018 | 2853 | 0.110 |
Why?
|
| Spectrum Analysis | 1 | 2014 | 144 | 0.110 |
Why?
|
| Medical Oncology | 1 | 2021 | 1462 | 0.110 |
Why?
|
| Survival Rate | 3 | 2021 | 12530 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 2672 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2000 | 709 | 0.100 |
Why?
|
| Pregnancy | 2 | 2023 | 8089 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 1331 | 0.100 |
Why?
|
| Tissue Donors | 1 | 1996 | 812 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2017 | 698 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2015 | 487 | 0.100 |
Why?
|
| Lasers, Dye | 1 | 2010 | 2 | 0.090 |
Why?
|
| Lasers, Gas | 1 | 2010 | 14 | 0.090 |
Why?
|
| United States | 2 | 2020 | 16036 | 0.090 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2010 | 207 | 0.090 |
Why?
|
| Texas | 1 | 2021 | 6434 | 0.090 |
Why?
|
| ErbB Receptors | 1 | 2019 | 2383 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2020 | 3069 | 0.090 |
Why?
|
| Precancerous Conditions | 1 | 2016 | 1065 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2017 | 2287 | 0.090 |
Why?
|
| Equipment Design | 2 | 2014 | 1206 | 0.080 |
Why?
|
| Hypertension | 1 | 2017 | 1617 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2017 | 9467 | 0.070 |
Why?
|
| Disease Progression | 4 | 2023 | 6905 | 0.070 |
Why?
|
| Quality of Life | 1 | 2021 | 4745 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2018 | 13385 | 0.070 |
Why?
|
| Algorithms | 1 | 2017 | 3922 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 5420 | 0.060 |
Why?
|
| Animals | 3 | 2019 | 62757 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 4963 | 0.060 |
Why?
|
| Amides | 1 | 2023 | 118 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 4993 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 7788 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2020 | 3538 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 5113 | 0.050 |
Why?
|
| Ligands | 1 | 2023 | 1057 | 0.050 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 2417 | 0.050 |
Why?
|
| Drug Dosage Calculations | 1 | 2020 | 46 | 0.040 |
Why?
|
| Neck Dissection | 1 | 2021 | 294 | 0.040 |
Why?
|
| Veins | 1 | 2021 | 166 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2020 | 4070 | 0.040 |
Why?
|
| DNA Mutational Analysis | 2 | 2016 | 2365 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2015 | 1618 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 3150 | 0.040 |
Why?
|
| Carcinoma | 1 | 2010 | 2623 | 0.040 |
Why?
|
| 2-Propanol | 1 | 2018 | 8 | 0.040 |
Why?
|
| Back | 1 | 2018 | 49 | 0.040 |
Why?
|
| Mice | 2 | 2016 | 36006 | 0.040 |
Why?
|
| Keratosis | 1 | 2018 | 37 | 0.040 |
Why?
|
| Young Adult | 4 | 2020 | 22094 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 16606 | 0.040 |
Why?
|
| Pigmentation Disorders | 1 | 2018 | 42 | 0.040 |
Why?
|
| Eccrine Glands | 1 | 2017 | 5 | 0.040 |
Why?
|
| Venous Pressure | 1 | 2017 | 17 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2018 | 258 | 0.040 |
Why?
|
| Leg | 1 | 2018 | 216 | 0.040 |
Why?
|
| Age Factors | 2 | 2017 | 5509 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 1439 | 0.040 |
Why?
|
| Sclerotherapy | 1 | 2017 | 47 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 447 | 0.030 |
Why?
|
| Mice, Hairless | 1 | 2016 | 57 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 1996 | 56 | 0.030 |
Why?
|
| Corneal Transplantation | 1 | 1996 | 51 | 0.030 |
Why?
|
| Needles | 1 | 2016 | 107 | 0.030 |
Why?
|
| Corneal Injuries | 1 | 1996 | 31 | 0.030 |
Why?
|
| Lasers, Excimer | 1 | 1996 | 99 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 1996 | 379 | 0.030 |
Why?
|
| Walking | 1 | 2018 | 274 | 0.030 |
Why?
|
| Hyperopia | 1 | 1996 | 84 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2017 | 319 | 0.030 |
Why?
|
| Zinc Finger Protein Gli2 | 1 | 2015 | 30 | 0.030 |
Why?
|
| Body Weight | 1 | 2020 | 1334 | 0.030 |
Why?
|
| Disease Transmission, Infectious | 1 | 1996 | 101 | 0.030 |
Why?
|
| Patched Receptors | 1 | 2015 | 48 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 4998 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2017 | 284 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 691 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 2270 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2016 | 591 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2017 | 417 | 0.030 |
Why?
|
| Astigmatism | 1 | 1996 | 178 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 4352 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1996 | 1532 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2015 | 280 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 1827 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2014 | 209 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 679 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 1996 | 507 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 4967 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 3976 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 1323 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 1500 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2018 | 1550 | 0.020 |
Why?
|
| Visual Acuity | 1 | 1996 | 864 | 0.020 |
Why?
|
| Endovascular Procedures | 1 | 2017 | 469 | 0.020 |
Why?
|
| Recurrence | 1 | 2020 | 4884 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 911 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2013 | 835 | 0.020 |
Why?
|
| Binding Sites | 1 | 2015 | 2298 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 1755 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2016 | 1037 | 0.020 |
Why?
|
| Exome | 1 | 2015 | 1250 | 0.020 |
Why?
|
| Patient Safety | 1 | 2015 | 655 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 1555 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 2574 | 0.020 |
Why?
|
| Mutation | 2 | 2019 | 15913 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 2349 | 0.020 |
Why?
|
| Adolescent | 2 | 2019 | 32609 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2015 | 1730 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 1996 | 6208 | 0.020 |
Why?
|
| Genomics | 1 | 2016 | 2830 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 5566 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 5180 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2015 | 9323 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 3472 | 0.010 |
Why?
|
| Risk Factors | 1 | 2020 | 18016 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2015 | 6876 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 12008 | 0.010 |
Why?
|